Imprimis Pharmaceuticals, Inc. has signed a three-year exclusive sales representation agreement with Precision Lens to help expand Imprimis' ophthalmic portfolio into select geographies of the United States, primarily focused in 13 states in the U.S. Midwest.
Precision Lens, which reportedly sells and distributes more than 60 percent of the intraocular lens (IOLs) for cataract surgery in its markets, will add resources to exclusively sell Imprimis' pharmaceutical products, including Dropless Therapy®, LessDrops® combination eye drops, Simple Drops™ preservative-free glaucoma drops, MKO Melt™ conscious sedation, and medications typically used for dilation, general inflammation and infection.
Imprimis will reportedly continue to focus its sales efforts in all 50 states and provide support to new accounts procured by Precision Lens.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Imprimis Pharmaceuticals, Inc.